Unrelated donor hematopoietic stem cell transplantation for infantile enteropathy due to IL-10/IL-10 receptor defect

Pediatric Transplantation
Adam GassasTal Schechter

Abstract

Recent advances in genetic diagnosis have identified mutations in gene encoding interleukin-10 (IL-10) and IL-10 receptor (IL-10R) proteins as a cause for early-onset enterocolitis leading to hyperinflammatory immune response. Allogeneic HSCT offers a potential cure; however, it was only performed in a few infants and mainly from family-related donors. We report a case of a girl who presented very early in life with severe infantile enterocolitis. Gene sequencing confirmed IL-10R defect. Her older sister died at 13 months of age from severe undiagnosed enterocolitis. There was no family donor. An unrelated search identified a potential 10/10 high-resolution HLA-matched donor. There was some delay in donor activation because IL-10R defect was not on the standard list of indications for unrelated HSCT. Our patient received the unrelated HSCT at seven months of age, and she is currently nine months after transplant and doing very well. Because HSCT is the curative option of choice for this disorder, we encourage adding IL-10 and IL-10R protein defects to the list of HSCT indications for unrelated donor procurement.

References

Mar 13, 2001·Annual Review of Immunology·K W MooreA O'Garra
Nov 6, 2009·The New England Journal of Medicine·Erik-Oliver GlockerChristoph Klein
Oct 12, 2010·Lancet·Erik-Oliver GlockerBodo Grimbacher
Apr 27, 2011·The American Journal of Gastroenterology·Bernadette BegueFrank M Ruemmele
May 3, 2012·Inflammatory Bowel Diseases·Christopher J MoranAleixo M Muise
Nov 20, 2012·The Journal of Allergy and Clinical Immunology·Karin R EngelhardtErik-Oliver Glocker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
Annika KischMariette Bengtsson
Hematology/oncology Clinics of North America
Javid Gaziev, Guido Lucarelli
© 2021 Meta ULC. All rights reserved